SouthState Corp Has $16.97 Million Stake in Johnson & Johnson (NYSE:JNJ)

SouthState Corp boosted its position in Johnson & Johnson (NYSE:JNJFree Report) by 1.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,947 shares of the company’s stock after buying an additional 1,519 shares during the period. Johnson & Johnson makes up approximately 1.6% of SouthState Corp’s portfolio, making the stock its 16th biggest position. SouthState Corp’s holdings in Johnson & Johnson were worth $16,968,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Hibernia Wealth Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at about $27,000. FNY Investment Advisers LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth approximately $37,000. Tower View Wealth Management LLC increased its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares in the last quarter. Creative Capital Management Investments LLC increased its holdings in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $48,000. 68.40% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.1 %

Shares of Johnson & Johnson stock opened at $157.98 on Thursday. The company’s fifty day simple moving average is $158.20 and its 200-day simple moving average is $159.04. The stock has a market capitalization of $380.30 billion, a PE ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the company earned $2.35 EPS. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. As a group, equities analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.01%. Johnson & Johnson’s payout ratio is 34.47%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. Barclays boosted their price objective on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $180.00 in a report on Friday, December 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Tuesday. Finally, Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $176.14.

Get Our Latest Report on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.